Optimas Capital’s Novavax NVAX Stock Holding History

Optimas Capital’s Portfolio NVAX Stock Details NVAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-27,800	Closed	-$2.05M	–	33
2022 Q1	$2.05M	Buy	+27,800	New	+$2.48M	1.92%	17

Other funds holding NVAX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Voloridge Investment Management Jupiter, Florida $25B AUM 28.08% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Optimas Capital's NVAX Position: Q2 2022 in Review

Optimas Capital sold out of Novavax (NVAX) in Q2 2022, closing a stake of 27,800 shares — an estimated $2.05M sold.

Optimas Capital first reported a position in NVAX in Q1 2022 and held it in 1 quarter. The position peaked at $2.05M in Q1 2022. 325 funds tracked by Wall St. Rank hold NVAX as of Q2 2022.

Optimas Capital reported no remaining Novavax position as of Q2 2022 after selling out during the quarter.
Optimas Capital sold 27,800 Novavax shares in Q2 2022, an estimated $2.05M.
Optimas Capital first reported a position in Novavax in Q1 2022 and held it in 1 quarter.
Optimas Capital's Novavax position peaked at $2.05M in Q1 2022.
325 funds tracked by Wall St. Rank held Novavax as of Q2 2022.

Based on Optimas Capital's 13F filing for Q2 2022, filed 12 Aug 2022.